Literature DB >> 29788053

Reversing Ongoing Chronic Intestinal Inflammation and Fibrosis by Sustained Block of IL-12 and IL-23 Using a Vaccine in Mice.

Qingdong Guan1,2,3,4, Carolyn R Weiss1,2, Shuhe Wang5, Gefei Qing6, Xi Yang1,5, Richard J Warrington1,7, Charles N Bernstein7, Zhikang Peng1,2.   

Abstract

© 2018 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  IL-12/IL-23p40 vaccine; TNBS-induced colitis; and DSS-induced colitis; immunotherapy

Mesh：

Substances：

Year:  2018        PMID： 29788053      PMCID： PMC6205364          DOI： 10.1093/ibd/izy142

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN： 1078-0998            Impact factor:   5.325


  46 in total

1.  A novel function of IL-12p40 as a chemotactic molecule for macrophages.

Authors:  S J Ha; C H Lee; S B Lee; C M Kim; K L Jang; H S Shin; Y C Sung
Journal:  J Immunol       Date:  1999-09-01       Impact factor: 5.422

Review 2.  IL-12-and IL-23 in health and disease.

Authors:  Andrew L Croxford; Paulina Kulig; Burkhard Becher
Journal:  Cytokine Growth Factor Rev       Date:  2014-08-01       Impact factor: 7.638

3.  Immunity to Chlamydia trachomatis is mediated by T helper 1 cells through IFN-gamma-dependent and -independent pathways.

Authors:  L L Perry; K Feilzer; H D Caldwell
Journal:  J Immunol       Date:  1997-04-01       Impact factor: 5.422

4.  Adoptive transfer of CD8alpha+ dendritic cells (DC) isolated from mice infected with Chlamydia muridarum are more potent in inducing protective immunity than CD8alpha- DC.

Authors:  Laura Bilenki; Shuhe Wang; Jie Yang; Yijun Fan; Lei Jiao; Antony George Joyee; Xiaobing Han; Xi Yang
Journal:  J Immunol       Date:  2006-11-15       Impact factor: 5.422

5.  Interleukin-12 antagonist activity of mouse interleukin-12 p40 homodimer in vitro and in vivo.

Authors:  M K Gately; D M Carvajal; S E Connaughton; S Gillessen; R R Warrier; K D Kolinsky; V L Wilkinson; C M Dwyer; G F Higgins; F J Podlaski; D A Faherty; P C Familletti; A S Stern; D H Presky
Journal:  Ann N Y Acad Sci       Date:  1996-10-31       Impact factor: 5.691

Review 6.  Future directions in inflammatory bowel disease management.

Authors:  Geert R D'Haens; R Balfour Sartor; Mark S Silverberg; Joel Petersson; Paul Rutgeerts
Journal:  J Crohns Colitis       Date:  2014-04-16       Impact factor: 9.071

Review 7.  The immunological and genetic basis of inflammatory bowel disease.

Authors:  Gerd Bouma; Warren Strober
Journal:  Nat Rev Immunol       Date:  2003-07       Impact factor: 53.106

Review 8.  Vaccination with cytokines in autoimmune diseases.

Authors:  Laure Delavallée; Eric Assier; Anne Denys; Géraldine Falgarone; Jean-François Zagury; Sylvianne Muller; Natacha Bessis; Marie-Christophe Boissier
Journal:  Ann Med       Date:  2008       Impact factor: 4.709

9.  IL-17/Th17 promotes type 1 T cell immunity against pulmonary intracellular bacterial infection through modulating dendritic cell function.

Authors:  Hong Bai; Jianjun Cheng; Xiaoling Gao; Antony George Joyee; Yijun Fan; Shuhe Wang; Lei Jiao; Zhi Yao; Xi Yang
Journal:  J Immunol       Date:  2009-10-07       Impact factor: 5.422

10.  MyD88 signalling plays a critical role in host defence by controlling pathogen burden and promoting epithelial cell homeostasis during Citrobacter rodentium-induced colitis.

Authors:  D L Gibson; C Ma; K S B Bergstrom; J T Huang; C Man; B A Vallance
Journal:  Cell Microbiol       Date:  2007-11-02       Impact factor: 3.715
View more
  8 in total

Review 1.  Revisiting fibrosis in inflammatory bowel disease: the gut thickens.

Authors:  Silvia D'Alessio; Federica Ungaro; Daniele Noviello; Sara Lovisa; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-12-07       Impact factor: 46.802

2.  Peptide YY 3-36 attenuates trinitrobenzene sulfonic acid-induced colitis in mice by modulating Th1/Th2 differentiation.

Authors:  Zhiqiang Li; Xiaoyuan Kuang; Tao Chen; Tao Shen; Jiahong Wu
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

3.  Sustained suppression of IL-18 by employing a vaccine ameliorates intestinal inflammation in TNBS-induced murine colitis.

Authors:  Qingdong Guan; Richard Warrington; Sem Moreno; Gefei Qing; Carolyn Weiss; Zhikang Peng
Journal:  Future Sci OA       Date:  2019-07-30

Review 4.  All are Equal, Some are More Equal: Targeting IL 12 and 23 in IBD - A Clinical Perspective.

Authors:  André Jefremow; Markus F Neurath
Journal:  Immunotargets Ther       Date:  2020-11-26

Review 5.  Intestinal Fibrosis in Inflammatory Bowel Disease and the Prospects of Mesenchymal Stem Cell Therapy.

Authors:  Yifei Wang; Bin Huang; Tao Jin; Dickson Kofi Wiredu Ocansey; Jiajia Jiang; Fei Mao
Journal:  Front Immunol       Date:  2022-03-18       Impact factor: 7.561

6.  Convergent and criterion validity of PROMIS anxiety measures relative to six legacy measures and a structured diagnostic interview for anxiety in cancer patients.

Authors:  Kerrie Clover; Sylvie D Lambert; Christopher Oldmeadow; Benjamin Britton; Alex J Mitchell; Gregory Carter; Madeleine T King
Journal:  J Patient Rep Outcomes       Date:  2022-07-20

Review 7.  Prevention and Treatment of Stricturing Crohn's Disease - Perspectives and Challenges.

Authors:  Joseph Sleiman; Sara El Ouali; Taha Qazi; Benjamin Cohen; Scott R Steele; Mark E Baker; Florian Rieder
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2020-12-28       Impact factor: 3.869

Review 8.  A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease.

Authors:  Qingdong Guan
Journal:  J Immunol Res       Date:  2019-12-01       Impact factor: 4.818
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.